NEW YORK, January 1, 2026, 21:17 ET — Market closed
- Cytokinetics shares last closed up 3.5% at $63.54, ahead of the company’s planned January commercial launch of Myqorzo.
- A regulatory filing showed EVP Andrew Callos sold 1,809 shares under a prearranged trading plan.
- Investors are watching for U.S. pricing details, early prescriptions and the next earnings update expected in late February.
Cytokinetics, Incorporated shares ended Wednesday up 3.5% at $63.54, the final U.S. trading session of 2025, after markets closed Thursday for the New Year’s Day holiday. The stock has traded between $29.31 and $70.98 over the past 52 weeks, according to market data.
The year-end move matters because Cytokinetics is weeks away from its first full-scale commercial test. Investors have been valuing the biotech on clinical data and regulatory milestones; the next swing factor is execution in the field.
In mid-December, the company said the U.S. Food and Drug Administration approved Myqorzo (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy, a heart muscle disease that can block blood flow. The drug carries a boxed warning for risk of heart failure and is available only through a Risk Evaluation and Mitigation Strategy (REMS), a safety program that can require additional monitoring. “This is a historic moment for our company and for the patients we serve,” Chief Executive Robert I. Blum said at the time. ir.cytokinetics.com
A Form 4 filing dated Dec. 30 showed Executive Vice President and Chief Commercial Officer Andrew Callos sold 1,809 shares at an average price of $62.44 on Dec. 29. The filing showed Callos still held 51,353 shares after the transaction.
The form indicated the sale was made under a Rule 10b5-1 plan, a preset instruction that allows insiders to trade on a schedule set in advance, rather than at their discretion.
Myqorzo is entering a market already served by Bristol Myers Squibb’s Camzyos, with Cytokinetics aiming to carve out share as doctors compare labels, monitoring requirements and real-world tolerability. The company has said it plans to announce U.S. pricing details before the launch.
That makes the next few weeks a “tell” for demand: how quickly specialist centers write first prescriptions, what insurers require for coverage, and whether REMS administration proves a speed bump or a manageable step in routine care.
Technically, Cytokinetics is trading close to its 50-day moving average of about $63 and well above its 200-day moving average near $46, levels traders often use to gauge short- and long-term momentum.
Outside the U.S., Cytokinetics has pointed to pending regulatory milestones that could affect sentiment in 2026. In Europe, the company said the CHMP backed Myqorzo in December and that a European Commission decision is expected in the first quarter.
In China, Cytokinetics said an approval earlier in December triggered a $7.5 million milestone payment from Sanofi under their Greater China licensing deal.
The next scheduled financial checkpoint is earnings. Cytokinetics has not confirmed a date, but Zacks Investment Research estimates results on Feb. 26, with a forecast loss of $1.48 per share.
Before the next session on Friday, traders will also watch the macro tape. The Institute for Supply Management’s December manufacturing index is due at 10 a.m. ET, a read that can move rates and risk appetite across growth stocks.
The next major U.S. data point is the December jobs report on Jan. 9 at 8:30 a.m. ET, which can influence interest-rate expectations that often bleed into biotech valuations.
For Cytokinetics, the nearer-term catalysts remain company-specific: a pricing update, first-week prescription trends once Myqorzo ships, and any new regulatory or SEC filings that add clarity around launch execution.
